title: Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
abstract: Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM(+)) and 900 subjects who did not receive IM before HCT (IM(-)) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA, USA. sjlee@fhcrc.org
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Lee
authors.forename: Manisha
authors.initials: M
authors.lastname: Kukreja
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Giralt
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Szer
authors.forename: Mukta
authors.initials: M
authors.lastname: Arora
authors.forename: Ann E
authors.initials: AE
authors.lastname: Woolfrey
authors.forename: Francisco
authors.initials: F
authors.lastname: Cervantes
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
authors.forename: Robert Peter
authors.initials: RP
authors.lastname: Gale
authors.forename: Joerg
authors.initials: J
authors.lastname: Halter
authors.forename: Armand
authors.initials: A
authors.lastname: Keating
authors.forename: David I
authors.initials: DI
authors.lastname: Marks
authors.forename: Philip L
authors.initials: PL
authors.lastname: McCarthy
authors.forename: Eduardo
authors.initials: E
authors.lastname: Olavarria
authors.forename: Edward A
authors.initials: EA
authors.lastname: Stadtmauer
authors.forename: Manuel
authors.initials: M
authors.lastname: Abecasis
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: H Jean
authors.initials: HJ
authors.lastname: Khoury
authors.forename: Biju
authors.initials: B
authors.lastname: George
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Hale
authors.forename: Jane L
authors.initials: JL
authors.lastname: Liesveld
authors.forename: David A
authors.initials: DA
authors.lastname: Rizzieri
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Antin
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Bolwell
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Carabasi
authors.forename: Edward
authors.initials: E
authors.lastname: Copelan
authors.forename: Osman
authors.initials: O
authors.lastname: Ilhan
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: Harold C
authors.initials: HC
authors.lastname: Schouten
authors.forename: Axel R
authors.initials: AR
authors.lastname: Zander
authors.forename: Mary M
authors.initials: MM
authors.lastname: Horowitz
authors.forename: Richard T
authors.initials: RT
authors.lastname: Maziarz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006680:HLA Antigens / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012042:Registries; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D006680:HLA Antigens; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate